Lipid abnormalities after cardiac transplantation
- Howard J Eisen, MD
Howard J Eisen, MD
- Thomas J Vischer Professor of Medicine
- Drexel University College of Medicine
- Section Editors
- Sharon A Hunt, MD
Sharon A Hunt, MD
- Editor-in-Chief — Cardiovascular Medicine
- Section Editor — Heart Transplantation
- Professor of Medicine
- Stanford University School of Medicine
- Mason W Freeman, MD
Mason W Freeman, MD
- Section Editor — Lipids
- Professor of Medicine
- Harvard Medical School
Hyperlipidemia occurs in 60 to 83 percent of heart transplant recipients treated with modern, conventional immunosuppressive therapy [1-6]. The abnormalities that occur include elevations in the serum levels of total and low density lipoprotein (LDL) cholesterol and in serum triglycerides (TG).
The magnitude of these effects was illustrated in a study of 100 heart transplant recipients who survived more than three months after surgery . The following differences were noted between the baseline and three month values; there were no significant further increases over time:
●Total cholesterol – 168 to 234 mg/dL (4.4 to 6.1 mmol/L)
●LDL cholesterol – 111 to 148 mg/dL (2.9 to 3.8 mmol/L)
●High density lipoprotein (HDL) cholesterol – 34 to 47 mg/dL (0.9 to 1.2 mmol/L)To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992; 19:1315.
- Becker DM, Markakis M, Sension M, et al. Prevalence of hyperlipidemia in heart transplant recipients. Transplantation 1987; 44:323.
- Becker DM, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988; 85:632.
- Stamler JS, Vaughan DE, Loscalzo J. Immunosuppressive therapy and lipoprotein abnormalities after cardiac transplantation. Am J Cardiol 1991; 68:389.
- Taylor DO, Thompson JA, Hastillo A, et al. Hyperlipidemia after clinical heart transplantation. J Heart Transplant 1989; 8:209.
- Rudas L, Pflugfelder PW, McKenzie FN, et al. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol 1990; 66:1135.
- Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621.
- Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96:1398.
- Kubo SH, Peters JR, Knutson KR, et al. Factors influencing the development of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1992; 70:520.
- Laufer G, Grablowitz V, Laczkovics A, et al. The determinants of elevated total plasma cholesterol levels in cardiac transplant recipients administered low dose cyclosporine for immunosuppression. J Thorac Cardiovasc Surg 1992; 104:241.
- Lake KD, Reutzel TJ, Pritzker MR, et al. The impact of steroid withdrawal on the development of lipid abnormalities and obesity in heart transplant recipients. J Heart Lung Transplant 1993; 12:580.
- Stamler JS, Vaughan DE, Rudd MA, et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1988; 62:1268.
- Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 1996; 50:538.
- Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54:868.
- Renlund DG, Bristow MR, Crandall BG, et al. Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunosuppression. J Heart Transplant 1989; 8:214.
- Hilbrands LB, Demacker PN, Hoitsma AJ, et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5:2073.
- Kasiske BL, Tortorice KL, Heim-Duthoy KL, et al. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 1991; 17:700.
- Kuster GM, Drexel H, Bleisch JA, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 1994; 57:1479.
- Steinmüller TM, Gräf KJ, Schleicher J, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. Transplantation 1994; 58:669.
- Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48:37.
- Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005; 24:1736.
- Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003; 107:93.
- Bilchick KC, Henrikson CA, Skojec D, et al. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 2004; 148:200.
- Koshman SL, Lalonde LD, Burton I, et al. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 2005; 39:1561.
- http://www.fda.gov/Drugs/DrugSafety/ucm283137.htm (Accessed on January 03, 2012).
- Stapleton DD, Mehra MR, Dumas D, et al. Lipid-lowering therapy and long-term survival in heart transplantation. Am J Cardiol 1997; 80:802.
- Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71.
- Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med 1990; 112:228.
- Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85:544.
- Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94:13.
- Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol 1994; 74:499.
- Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399.
- Weis M, Pehlivanli S, Meiser BM, von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001; 38:814.
- Hölschermann H, Hilgendorff A, Kemkes-Matthes B, et al. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation 2000; 69:1830.
- Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105:2341.
- Keogh A, Macdonald P, Kaan A, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19:529.
- Ballantyne CM, Bourge RC, Domalik LJ, et al. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol 1996; 78:532.
- Carrier M, Pelletier GB, Genest J Jr, et al. Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation. Ann Thorac Surg 1994; 57:353.
- Barbir M, Rose M, Kushwaha S, et al. Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation. Int J Cardiol 1991; 33:241.
- Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82:IV281.
- Vanhaecke J, Van Cleemput J, Van Lierde J, et al. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994; 58:42.
- Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92:77.
- Keogh A, Day R, Critchley L, et al. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc 1988; 20:27.
- Mueller EA, Kovarik JM, van Bree JB, et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57:1178.
- Jaeger BR, Schirmer J, Thiery J, et al. Coronary risk factor management for the prevention and treatment of graft vessel disease in heart transplant patients. Ther Apher 1999; 3:214.
- Park JW, Merz M, Braun P. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J Heart Lung Transplant 1997; 16:290.
- ETIOLOGY OF HYPERLIPIDEMIA
- Calcineurin inhibitors
- RATIONALE FOR THERAPY
- APPROACH TO THERAPY
- General approach
- - Clinical trials
- - Side effects and drug interactions
- Fibric acid derivatives
- - Nicotinic acid
- - Bile acid sequestrants
- - Ezetimibe
- - LDL apheresis
- - PCSK9 inhibitors
- Goal LDL cholesterol
- SOCIETY GUIDELINE LINKS
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS